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Purpose: Smoking has been associated with an increased risk of developing multiple sclerosis, disease pro-
gression and clinical disability. We detected the effects of smoking on regional brain volumes and lesion load in
patients with clinically isolated syndrome using quantitative magnetic resonance imaging. Materials and Meth-
ods: Smoker patients (n = 16), smoker healthy controls (n = 13), non-smoker patients (n = 17) and non-smoker
healthy controls (n = 14) underwent magnetic resonance imaging and neocortical volumes were measured. Le-
sion load was calculated in terms of number and volume of white matter hyperintensities. Results: Smoking was
associated with increased gray matter volumes in several regions of the brain. A tendency towards greater lesion
load in smoker patients was found. Smoking duration was significantly negatively correlated with intracranial vol-
ume and left hemisphere cortical gray matter volume. There was no relationship between regional brain volumes
and clinical disability scores, lesion load duration of the disease and degree of smoking exposure. Conclusions:
Clinically isolated syndrome related regional brain atrophy might vary in extent and severity with smoking. De-
spite increased lesion load, less cortical and deep gray matter damage with a possible neuroprotective effect
occurs in smoking.
KEYWORDS: clinically isolated syndrome, cigarette smoking, brain volume
Introduction
Multiple sclerosis (MS) is a chronic inflammatory de-
myelinating disease of the central nervous system (CNS)
with a complex etiology that predominantly affects
young adults [1].
With limited availability of the epidemiologic MS
studies in Turkey, the prevalence of MS seems between
34/1000.000 and 101/100.000 in different districts of
Turkey [2,3]. Although patients usually recover from
their presenting episode, clinically isolated syndrome
(CIS) often converts into MS even with increased rates
if associated with several risk factors [4,5]. Of the envi-
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ronmental factors, cigarette smoking not only increases
the risk of development of CIS to MS, but also modifies
the clinical course of the disease [4].
Nicotine has been held responsible for the major-
ity of the detrimental effects of smoking on the CNS
[6–8]. It acts as an agonist within the cholinergic neu-
rotransmitter system and nicotinic receptors are widely
distributed within the CNS with the highest density in
the thalami [6,9,10]. Although there has been some in-
consistency in the results, magnetic resonance imaging
(MRI) has been used as a tool to demonstrate the smok-
ing related changes on the CNS: smaller gray matter
(GM) [7,11,12] and white matter (WM) [13,14] brain
volumes as well as greater corpus callosum (CC) volume
[8]. Also Gazdzinski et al. found that chronic smoking in
alcohol dependence was associated with more temporal
WM volume [15].
MRI is an essential part of the diagnostic criteria in
MS. Although atrophy of brain tissue is not included in
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MS diagnostic criteria, decreased global or regional GM
volumes in patients with CIS have been associated with
a higher rate of conversion to MS [16,17].
In this study, it was aimed to determine whether
smoking would result in distinct alterations in regional
brain volumes of patients with CIS as assessed by quan-
titative MRI. In addition, the relationship was examined
between smoking duration, age at onset of smoking and
regional brain volumes. The secondary objective of the
study was to evaluate the potential influence of smoking
on lesion load in patients with CIS.
Materials and methods
Participants
The institutional review board approved the study. All
participants gave written informed consent.
A total of 60 right-handed, equivalently educated
subjects participated in our cross-sectional study.
Healthy subjects and patients were collected in four
age-matched groups according to smoking habits and
presence of CIS: CISs (n = 16; F/M = 8/8; mean age
(±SD) = 34.3 (±8.9) years), HCs (n = 13; F/M =
6/7; mean age (±SD) = 33.7 (±7.4) years), CISns
(n = 17; F/M = 13/4; mean age (±SD) = 29.7
(±6.9) years) and HCns (n = 14; F/M = 10/4; mean
age (±SD) = 29.8 (±7.9) years). Non-smoker partici-
pants had smoked no more than five cigarettes in their
lifetime.
Twenty-seven healthy volunteers were recruited from
e-mail based on advertisement and volunteers from hos-
pital workers. Those individuals underwent systemic
and neurological examination and their medical records
were reviewed. Healthy participants with any history of
either substance abuse or dependence disorders other
than nicotine dependence and contraindications toMRI
were excluded from the study.
Thirty-three consecutive patients admitted to our
instiution during the years 2012–2014 were included in
the study. All patients fulfilled theMcDonald diagnostic
criteria for MS but had only one clinical episode con-
taining optic neuritis, cervical and/or thoracic myelitis
or brainstem/cerebellar syndrome. Exclusion criteria
for the patients were the presence of any systemic or
neurological disease other than CIS, receiving steroid
therapy or having an attack within 4 weeks of the MRI
scan. No cases were converted to clinically definite MS
during the study. Same patients also constituted the
participants of another MRI study on diffusion tensor
imaging alterations.
All patients were evaluated by two neurologists (S.
Diker, A. Tuncer) with 4 and 15 years of experience,
respectively, unaware of the MRI findings.
Image acquisition and analysis
All the participants had T1-weighted three-dimensional
(3D) high resolution images with 0.9 mm isotropic vox-
els (MPRAGE) (TR/TE: 2600/3.1 ms; matrix: 224 ×
256; NEX: 1; TA: 4.06; number of slices: 176; slice
thickness: 1.00 mm; distance factor: 50%; voxel size: 1
mm; in plane resolutions: 1 mm) and double inversion-
recovery sampling perfection with application opti-
mized contrasts using different flip angle evolution (DIR
SPACE) (TR/TE: 7500/325 ms; matrix: 192 × 192;
NEX: 1; TA: 6.09; number of slices: 144; slice thickness:
1.12 mm without intersection gap; voxel size: 1 mm;
in plane resolutions: 1 mm) imaging on a 3-Tesla MR
scanner (Magnetom, Tim, Siemens, Germany). DIR
SPACE sequence was used for better multiplanar de-
lineation of the lesions.
The imaging data were free of motion artifact and
no subject was discarded from the study. The measure-
ments of neocortical volumes (mm3) on 3D MPRAGE
T1WI were performed using FreeSurfer Version 4.5.1
(http://surfer.nmr.mgh.harvard.edu/). The automated
procedures for volumetric measures of the different
brain structures were described by Fischl et al. [18]. Fol-
lowing automated segmentation, normalization to to-
tal intracranial volume was obtained.The reconstructed
cortical surface models for each participant were manu-
ally inspected to ensure segmentation accuracy; regions
with poor segmentation accuracy due to poor image
quality or misregistration were excluded from further
statistical analyses. Cortical surfaces were automatically
parcellated and combined to create average volume for
total GM and for frontal, temporal, parietal and occipi-
tal lobar regions. The volume of T1 hypointense lesions
was also calculated automatically by this software.
The coordinations of each hyperintense WM lesion
on DIR SPACE imaging was recorded using BrainVoy-
ager QX 2.6 for Linux (http://www.brainvoyager.com).
The lesions were ranged by a bounding box in which
all the intensities of voxels were fixed to a threshold
for a clear visual distinction of lesions and parenchyma
(http://support.brainvoyager.com/volumespace/107-
volume-rendering/314-users-guide-masking-and-
cutting.html). The number of the voxels-of-interest
(VOIs) was calculated and the total volume of VOIs
where the lesions were ranged by bounding box. In this
way, it was aimed to determine the demyelinating hy-
perintense lesion load in respect of number and volume
of the lesions in the brain of patients with CIS. Patients
received intravenous gadopentetate dimeglumine (0.01
mmol/kg) contrast material and postcontrast axial
T1W 3D MPRAGE and coronal fat satureted images
(TR/TE = 550/15 ms; matrix = 256 × 256 NEX = 2)
were obtained at 5 min after injection in all patients to
detect active demyelinating lesion.
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Table 1. Baseline demographic characteristics, clinical data and smoking histories for all groups. mean (±SD).
CISns (n = 17) HCns (n = 14) CISs (n = 16) HCs (n = 13) p value
Age (years) 29.7 (± 6.9) 29.8 (± 7.9) 34.3 (± 8.9) 33.7 (± 7.4) P1 = 0.226
Gender (female/male) 13/4 10/4 8/8 6/7 P1 = 0.223
Pack-year – – 9.3 (± 10.1) 7.7 (± 4.7) p2 = 0.904
Cigarettes per day – – 14.3 (± 10.6) 12.9 (± 6.6) p2 = 0.760
Duration of smoking (years) – – 11.6 (± 8.5) 12.6 (± 8.8) p2 = 0.680
Age at onset of smoking (years) – – 20.6 (± 5.4) 21.0 (± 5.8) p2 = 0.716
Time lapse from clinical episode (months) 9.2 (± 7.0) – 10.8 (± 16.5) – p3 = 0.313
CISs smoker patients with clinically isolated syndrome, HCs smoker healthy controls, CISns non-smoker patients with clinically isolated
syndrome, HCns non-smoker healthy controls.
P1 values among all groups.
p2 values between all smoker individuals.
p3 values between patient groups.
Statistical analysis
Numerical variables were evaluated for normality
of data distribution using the Kolmogorov–Smirnov
test. Descriptive statistics were stated as mean ±
standard deviation. Independent samples t-test was
used to compare the means of two groups. The Mann
Whitney U test was used to compare two groups for
non-parametric data. A Spearman’s rho correlation
coefficient was used to investigate the relationship
between two variables. One-way analysis of variance
was applied to compare the differences between groups.
Multiple linear regression was performed to assess the
association between two or more independent variables
and a single continuous dependent variable. The anal-
ysis was also accessed to detect whether confounding
exists. The effect of group on dependent variables was
examined by multiple linear regression model, after
adjustment for age and sex. A value of p ≤ 0.05 was
accepted as statistically significant. Data analysis was
performed by IBM SPSS Statistics 21 software.
Results
Subjects and clinical characteristics
The patient group included 16 smokers (F/M = 8/8,
mean age (±SD) 34.3 (±8.9) years) and 17 non-
smokers (F/M = 13/4, mean age (±SD) 29.7 (±6.9)
years). The mean time lapse from clinical episodes for
CISs and CISns were 10.8 (± 16.5) and 9.2 (±7.0)
months, respectively. CISs and CISns had a mean ex-
panded disability status scale (EDSS) of 0.06 and 0.18,
respectively. Median EDSS of both patient groups is 0
(min = 0, max = 1).
The control group included 13 smokers (F/M =
6/7, mean age (±SD) 33.7 (±7.4) years) and 14 non-
smokers (10/4 = F/M, mean age (±SD) 29.8 (±7.9)
years).
The demographic information, clinical data and
smoking history are shown in Table 1. There was no sig-
nificant difference between CISs and HCs or between
CISns and HCns in terms of age and gender (all, p >
0.05). CISs and HCs showed no difference in exposure
to smoking (all, p > 0.05). CISs and CISns were similar
in duration of disease and EDSS (all, p > 0.05).
Volumetric comparisons in all groups
CISs had lower volume of bilateral hemispheric corti-
cal GM, total cortical GM, total GM, right cerebellar
cortex, right globus pallidus (GP), ventral diencephalon
(VDC), left hippocampus and bilateral thalami than
HCs (all, p ≤ 0.05). CISns had lower volume of subcor-
tical GM, left putamen, right GP and posterior CC than
HCns (all, p ≤ 0.05). There was no parenchymal cere-
bral region with a greater volume in patients when pa-
tients and control subjects were compared. The volume
of right lateral ventricle was higher in the patient groups
than in those of the matched controls. Furthermore,
compared toHCns, CISns showed significantly increased
volume of the cerebral spinal fluid (CSF). The regions
with statistically different volumes and their mean vol-
umes between the patients and control subjects are given
in Table 2.
When HCs and HCns were compared, the volumes of
bilateral cerebellar cortex, GP, VDC as well as thalami
were significantly greater in the smoking group (all, p ≤
0.05) (Table 3).
Among the patients, volume analysis revealed that
CISs had higher volumes of the intracranial, left cerebel-
lar cortex, left accumbens area and right GP than CISns.
There was no region of greater brain volume in CISns
relative to CISs (Table 4).
Regional brain volumes and lifetime exposure
to nicotine
Within overall smoking individuals, correlation analysis
revealed a significant negative relationship between the
C© 2015 Taylor and Francis
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Table 2. Brain regions that show significantly different volumes between patients and controls, their mean volumes (±SD) and p values.
Brain region CISs mean (±SD) (cm3) HCs mean (±SD) (cm3) p value
Hemispheric cortical GM (R) 222.6 (± 23.5) 242.1 (± 24.6) 0.017
Hemispheric cortical GM (L) 224.2 (± 24.4) 241.7 (± 25.2) 0.022
Total cortical GM 443.2 (± 47.3) 483.9 (± 49.7) 0.017
Total GM 622.8 (± 57.7) 681.0 (± 64.5) 0.004
Thalamus (L) 6.3 (± 0.9) 7.8 (± 1.1) 0.001
Thalamus (R) 6.5 (± 0.8) 8.3 (± 1.6) 0.001
Cerebellar cortex (R) 51.9 (± 5.5) 59.5 (± 8.0) 0.004
Hippocampus (L) 4.0 (± 0.3) 4.4 (± 0.3) 0.011
Globus pallidus (R) 1.4 (± 0.2) 1.7 (± 0.3) 0.003
VDC (R) 3.9 (± 0.5) 4.4 (± 0.6) 0.011
Lateral ventricle (R) 0.5 (± 0.1) 0.3 (± 0.1) 0.002
Brain region CISns mean (±SD) (cm3) HCns mean (±SD) (cm3) p value
Subcortical GM 149.4 (± 47.5) 180.9 (± 16.9) 0.030
Putamen (L) 5.1 (± 1.1) 5.9 (± 0.6) 0.050
GP (R) 1.3 (± 0.1) 1.4 (± 0.1) 0.006
Lateral ventricle (R) 0.4 (± 0.1) 0.2 (± 0.1) 0.009
CSF 1.0 (± 0.2) 0.8 (± 0.1) 0.032
CISs smoker patients with clinically isolated syndrome, HCs smoker healthy controls, CISns non-smoker patients with clinically isolated
syndrome, HCns non-smoker healthy controls, SD standard deviation, GM gray matter, R right, L left, VDC ventral diencephalon, GP
globus pallidus, CSF cerebral spinal fluid.
intracranial volume and pack-years (Spearman correla-
tion coefficient = −0.549; p = 0.003). Pack-years were
also significantly negatively correlated with left hemi-
sphere cortical GM (Spearman correlation coefficient =
−0.512; p = 0.006). (Figure 1).
Lesion load comparison between smoking
and non-smoking patients
The lesion load on T1W imaging as determined from
volumes of WM hypointensities was greater in smok-
ing patients than non-smoking patients (5.3 cm3 vs. 2.8
cm3; p= 0.05). CISs had a higher number and volume of
WMhyperintense lesion than CISns onDIR space imag-
ing, too. However, the difference did not reach statisti-
cal significance. (15 vs. 11 and 5.2 cm3 vs 2.4 cm3; p =
0.08 and 0.5). There was no correlation between DIR-
SPACE T2 hyperintense lesion load and significantly al-
tered regional brain volumes including intracranial, left
cerebellar cortex, left accumbens area and right GP.
Discussion
We found that smoking was associated with increased
GM volumes in several regions of the brain in both pa-
tients and controls. In contrast to the recent articles
showing smaller GM volumes [7,11,12,15], we found
that healthy smokers had greater GM volumes bilater-
ally in the cerebellar cortex, thalamus, globus pallidus
and VDC than healthy non-smokers. In this study, we
found similar effects of cigarette smoking in both healthy
controls and in patients with CIS compared to respec-
tive matched non-smoking individuals. Our finding of
Table 3. Brain regions with statistically different volumes between non-smoking and smoking healthy controls, their mean volumes
(±SD), p values.
Brain region HCns mean (±SD) (cm3) HCs mean (±SD) (cm3) p value
Cerebellar cortex (L) 49.0 (± 6.4) 56.2 (± 6.7) 0.026
Cerebellar cortex (R) 51.0 (± 6.3) 59.5 (± 8.0) 0.016
Thalamus (L) 6.6 (± 0.9) 7.8 (± 1.1) 0.049
Thalamus (R) 6.8 (± 0.9) 8.3 (± 1.6) 0.020
GP (L) 1.6 (± 0.09) 1.9 (± 0.3) 0.036
GP (R) 1.4 (± 0.1) 1.7 (± 0.3) 0.012
VDC (L) 3.6 (± 0.4) 4.3 (± 0.7) 0.050
VDC (R) 3.7 (± 0.3) 4.4 (± 0.6) 0.008
HCs smoker healthy controls, HCns non-smoker healthy controls, SD standard deviation, GM gray matter, L left, R right, GP globus
pallidus, VDC ventral diencephalon.
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Table 4. Brain regions with significantly different volumes in comparison to non-smoking and smoking patients, their mean values
(±SD), and p values.
Brain region CISns mean (±SD) (cm3) CISs mean (±SD) (cm3) p value
Intracranial volume 1294.3 (± 135.6) 1501.6 (± 106.5) 0.0001
Cerebellar cortex (L) 46.7 (± 5.0) 51.0 (± 6.5) 0.036
Accumbens area (L) 0.6 (± 0.1) 0.7 (± 0.1) 0.001
GP (R) 1.3 (± 0.1) 1.4 (± 0.2) 0.032
CISs smoker patients with clinically isolated syndrome, CISns non-smoker patients with clinically isolated syndrome, SD standard devia-
tion, L left, GP globus pallidus.
greater GM volumes in smoking relative to non-smoking
patients with CIS was also observed in schizophrenia
cases by Tregellas et al. demonstrating larger GM vol-
umes in lateral prefrontal and superior temporal gyri us-
ing voxel-based morphometry. The authors suggested
preservation of these areas in smoking group, in addition
to other regions belonging to prefrontal and limbic ar-
eas with decreased GM in the patients with schizophre-
nia [19]. Nicotinic acetylcholine receptor (nAChR)s are
extensively distributed in the human brain, with the
highest density in the thalamus, substantia nigra and
cerebral cortex in a decreasing order as well as cere-
bral vasculature and astrocytes [9,20–22]. Given the as-
sociations of brain region and subtype specific atten-
uations in nAChRs with neuropsychiatric diseases in-
cluding Alzheimer’s and Parkinson’s diseases, demen-
tia with Lewy bodies, schizophrenia and autism, stud-
ies revealing improvement following nicotine treatment
in the animal Parkinsonian models, and larger putamen
volumes in individuals with a greater lifetime nicotine
exposure, nicotine has been regarded to have a neu-
roprotective effect [22–24]. Either through mesolimbic
system activation by nicotine addiction or binding to
mostly concentrated nAChRs in the striatum, volume
changes in striatum with subsite-dependent alterations
have been reported. Our study differs in that our small
healthy group showed greater volumes of the GP, tha-
lamus cerebellar cortex and VDC than non-smokers.
Because our purpose was to study the effect of smok-
ing on brains with CIS, we did not focus on nicotine
dependence and measure Fagerström score, rather we
noted subjects’ lifetime use by pack-years. The finding
of greater lifetime exposure associated with lesser left
hemisphere cortical GM and total intracranial volume
is in line with previous studies showing correlations be-
tween pack-years of smoking andGMvolume [7,11,25].
Thus, along with previous cognitive study results, these
data suggest that the impact of chronic smoking on GM
volume may be an attenuation, in contrast to a sin-
gle one-time measurement compared with non-smokers
[26,27].
In the present study, patients with CIS had vol-
ume loss compared to matched individuals, in sev-
eral brain structures. This was more widespread in
CISs including the thalamus, hippocampus, cerebel-
lum, VDC and hemispheric cortical GM. Enlargement
of the lateral ventricle and CSF can be attributed to
volume reductions in the patient groups. Thus, in a
Figure 1. Scatterplot correlation results between regional brain volumes and smoking history in all smoking individuals (pack-years).
C© 2015 Taylor and Francis
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longitudinal study of 34 patients with CIS, Raz et al.
documented a progressive atrophy at 1-year follow-up
[17]. T1 hypointense WM lesion load was greater in
smoking patients than in non-smoking patients. We did
not find such a significant difference, although lesion
load was higher on DIR SPACE imaging, too. We be-
lieve these findings may have a clinical implication given
that non-enhancing demyelinating lesions on T1WI in
CIS patients are associated with a higher risk of con-
version to clinically definite MS along with the pres-
ence of T2 hyperintense lesions invisible on T1WI [28].
In relapsing–remitting MS, EDSS worsening over 10
years was found to best correlate with the combination
of baseline T1W lesion count and increasing T1W le-
sion volume [29]. One reason why Arikanoglu et al. did
not find an increased rate in conversion to MS despite
a higher lesion load in smoking CIS patients might have
been the measurement of only T2 hyperintense lesions
in their study. Smoking was associated with increased
T1hypo-, T2 hyperintense and contrast enhancing le-
sion volumes and reduced regional volumes in MS [30].
In addition to worse disease at baseline, smoker patients
withMS were faster in conversion to secondary progres-
sive disease on follow-up [31]. Also, in a 3-year follow-
up study of 129 patients with CIS, it was suggested that
smoking increased early conversion to MS after a clini-
cally isolated syndrome [4].
Regardless of smoking, we observed atrophy in the
thalamus, globus pallidus and putamen in our patients
with very low EDSS scores compared to healthy controls
as Henry et al. [32]. But, we cannot attribute deep GM
atrophy toWallerian degeneration fromWM lesions due
to lack of any correlation with neither EDSS nor lesion
load in this study. This is in contrast to the findings of
Tao et al., which suggested a link between subcortical
GM and WM atrophy based on significant positive cor-
relations with demyelinating lesions and clinical disabil-
ity in MS patients [33]. The reason why we cannot find
out any relation similar to Tao et al. is probably lower
lesion load and EDSS scores in CIS patients compared
to patients with MS.
The major noteworthy limitation in this study is the
relative small sample sizes of our patient and control
groups. One reason for that was the difficulty of hav-
ing two matched control groups according to smoking
habits of the patients. Due to small sample size we chose
to not use Bonferroni correction for statistical analysis.
Because, when sample size is small Bonferroni correc-
tion gives rise to increase of type II errors [34,35]. But,
it will be useful to make Bonferroni correction in the
studies which have larger sample size. Also, we could not
avoid relative female dominance in the non-smoker pa-
tient and control groups, because women usually show
fewer tendencies to smoking in our population. To elim-
inate this limitation, we used statistical sex and age
corrected analysis. Because this study concentrated on
CIS, our participants showed relatively younger age, and
in turn, less lifetime cigarette smoking compared with
previous studies on smoking in literature. These differ-
ences might have resulted in some statistical insignifi-
cance in the present study. Finally, because this study is
a cross-sectional study, it is carried out in a short time
and we could not estimate the conversion rate of CIS
to MS. Since no patient showed conversion to MS until
completion of the study. Future investigations consisting
of larger patient and control groups with longer follow-
up would give a more comprehensive understanding of
smoking-related effects on the occurrence and course of
demyelinating diseases.
Conclusion
The present study detected that CIS-related regional
brain atrophy varies in extent and severity with cigarette
smoking. Despite increased lesion load, less cortical and
deep GM damage with a possible neuroprotective effect
occurs in smoking.
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